Advertisement
Canada markets open in 10 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7288
    -0.0009 (-0.13%)
     

  • CRUDE OIL

    82.43
    -0.38 (-0.46%)
     

  • Bitcoin CAD

    86,499.41
    -4,228.92 (-4.66%)
     

  • CMC Crypto 200

    1,349.59
    -32.98 (-2.38%)
     

  • GOLD FUTURES

    2,334.80
    -3.60 (-0.15%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.7190
    +0.0670 (+1.44%)
     

  • NASDAQ futures

    17,366.25
    -298.25 (-1.69%)
     

  • VOLATILITY

    16.81
    +0.84 (+5.27%)
     

  • FTSE

    8,063.41
    +23.03 (+0.29%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6819
    0.0000 (0.00%)
     
MARKETS LIVE BLOG:

STOCK FUTURES SLIDE AFTER META'S REALITY CHECK, WITH GDP ON DECK

Owner of Facebook and Instagram plans to spend up to US$10B on AI infrastructure investments

BMRN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of December 22, 2021 in the Class Action Filed on Behalf of BioMarin Pharmaceutical Inc. Limited Shareholders

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - October 28, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) alleging that the Company violated federal securities laws.

Class Period: January 13, 2020 and September 3, 2021
Lead Plaintiff Deadline: December 22, 2021
No obligation or cost to you.

Learn more about your recoverable losses in BMRN:
https://www.kleinstocklaw.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?id=20757&from=5

BioMarin Pharmaceutical Inc. NEWS - BMRN NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase, was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the Food and Drug Administration would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

ADVERTISEMENT

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in BioMarin you have until December 22, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased BioMarin securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the BMRN lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101228